Clinical Trial

Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an 8-weeks, randomized controlled trial involving children under 6 years of age who meet clinical diagnostic criteria for RRTI. Participants are randomized to receive either probiotic or placebo. The primary clinical outcomes assessed are duration and frequency of respiratory symptoms and quality of life. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-01-31 -> 2026-06-30 2026-04-18
minor Completion pushed: 2026-01-31 -> 2026-06-30 2026-04-18
Trial Details
NCT Number NCT07297966
Lead Sponsor Min-Tze LIONG
Collaborators: Xinyi City People's Hospital
Conditions Recurrent Respiratory Tract Infections
Enrollment 120 participants
Start Date 2025-05-14
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-17